Pascal Longchamp
Oprichter bij Phistem SARL
Oorsprong van het eerstegraads netwerk van Pascal Longchamp
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.
16
| Subsidiary | Miscellaneous Commercial Services | 16 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Pascal Longchamp via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| BIOTAGE AB | Medical Specialties | Founder | |
Auda Pharmaceuticals ApS
 Auda Pharmaceuticals ApS Miscellaneous Commercial ServicesCommercial Services Part of Phytera, Inc., Auda Pharmaceuticals ApS provides proprietary combinatorial chemistry technologies. Auda Pharmaceuticals was acquired by Phytera, Inc. from Danish Development Finance Corp on March 17, 1997. | Miscellaneous Commercial Services | President | |
Auriga Partners SA
 Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | Investment Managers | Director/Board Member | |
Danmarks Eksport- og Investeringsfond
 Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
Quadrant Healthcare Plc
 Quadrant Healthcare Plc Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million. | Pharmaceuticals: Major | Director/Board Member | |
PNA Diagnostics A/S
 PNA Diagnostics A/S Medical SpecialtiesHealth Technology PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark | Medical Specialties | President | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director of Finance/CFO | |
| Technical University of Denmark | College/University | Graduate Degree Doctorate Degree | |
| TECHNOFLEX | Chemicals: Major Diversified | Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree | |
| University of Basel | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Founder Private Equity Investor | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sensimed SA
 Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Chairman Director/Board Member | |
AlchiMedics SA
 AlchiMedics SA Chemicals: Major DiversifiedProcess Industries AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France. | Chemicals: Major Diversified | Director/Board Member | |
| GX Biosystems A/S | President | ||
| EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member Chairman Director of Finance/CFO Founder Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO | |
Isocell SA
 Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | Food Retail | Director/Board Member | |
| Balliol College | College/University | Undergraduate Degree | |
| NANEXA AB | Medical Specialties | Director/Board Member | |
Nuevolution A/S
 Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
AntibioTx ApS
 AntibioTx ApS Pharmaceuticals: MajorHealth Technology AntibioTx ApS develops and manufactures pharmaceutical products. The private company is based in Kongens Lyngby, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
UNION Therapeutics A/S
 UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Founder | |
Unibio International Plc
 Unibio International Plc Financial ConglomeratesFinance Unibio International Plc is a leading British sustainable protein company that specializes in producing single-cell protein for animal feed. The company is based in London, UK, and David Henstrom has been the CEO since 2021. The company has won several awards for its environmentally friendly practices, including the "Kalundborg Business Council's Green Environment and Climate Award." Unibio has participated in various exhibitions and conferences worldwide, including the "Forum for Innovations in Agriculture" in 2018 and the "Deutsche Messe Hannover" in 2018. | Financial Conglomerates | Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Secretary | |
Synendos Therapeutics AG
 Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Medical Specialties | Director/Board Member Chairman | |
Double Bioventures Ltd.
 Double Bioventures Ltd. Miscellaneous Commercial ServicesCommercial Services Double Bioventures Ltd. is a British company founded in 2018 that builds non-traditional life-science companies in non-traditional ways. The private company is based in London, UK. The company focuses on identifying opportunities outside core therapeutics and developing robust business models for such businesses. The company aims to help life-science ventures play a wider role in meeting the challenges of the modern world. | Miscellaneous Commercial Services | Director/Board Member | |
Sundew ApS
 Sundew ApS Packaged SoftwareTechnology Services Sundew ApS targets water-borne pests and diseases. The company is based in Copenhagen, Denmark. and has subsidiaries in Ireland. The Danish company was founded in 2018 by Neil Goldsmith, Jørgen Hansen, Andy Gardiner. Giovanni Salerno has been the CEO of the company since 2021. | Packaged Software | Founder | |
Chosa ApS
 Chosa ApS Miscellaneous Commercial ServicesCommercial Services Chosa ApS is a Danish company that provides biotechnology services. The private company is based in Copenhagen, Denmark. The CEOs are Claus Frisenberg Pedersen and Neil Goldsmith. The company was founded in 2022. | Miscellaneous Commercial Services | Chief Executive Officer | |
| CHOSA ONCOLOGY AB | Miscellaneous Commercial Services | Chairman | |
| Zerion Pharma A/S | Director of Finance/CFO |
Statistieken
Internationaal
| Denemarken | 19 |
| Zwitserland | 11 |
| Frankrijk | 7 |
| Zweden | 6 |
| Verenigd Koninkrijk | 6 |
Sectoraal
| Health Technology | 27 |
| Commercial Services | 8 |
| Finance | 6 |
| Consumer Services | 5 |
| Process Industries | 3 |
Operationeel
| Director/Board Member | 106 |
| Corporate Officer/Principal | 41 |
| Chairman | 17 |
| Chief Executive Officer | 15 |
| Founder | 13 |
Sterkste connecties
| Insiders | |
|---|---|
| Søren Lemonius | 39 |
| Simon Jules Nebel | 23 |
| Jean-Philippe Tripet | 20 |
| Neil Goldsmith | 19 |
| Thomas Videbaek | 16 |
| Erich Schlick | 15 |
| Jakob Dynnes Hansen | 13 |
| Jutta Monika Heim | 12 |
| Patrick Scherrer | 10 |
| Jacques Mallet | 8 |
| Ben T. G. Tan | 8 |
| Jessica Mann | 8 |
| Steen Helde Hemmingsen | 7 |
| Melya Crameri | 6 |
| Sandy Dobbie | 4 |
- Beurs
- Insiders
- Pascal Longchamp
- Bedrijfsconnecties
